Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H39N5O8 |
Molecular Weight | 585.6487 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]4(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]4([H])C2)N(C)C
InChI
InChIKey=FPZLLRFZJZRHSY-HJYUBDRYSA-N
InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36,38-39,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1
Molecular Formula | C29H39N5O8 |
Molecular Weight | 585.6487 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB00560
https://en.wikipedia.org/wiki/Tigecycline
Curator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB00560
https://en.wikipedia.org/wiki/Tigecycline
Tigecycline (INN) is an antibiotic used to treat a number of bacterial infections. It is a first in class glycylcycline that is administered intravenously. For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes and Bacteroides fragilis. Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros. Tigecycline, a glycylcycline, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline carries a glycylamido moiety attached to the 9-position of minocycline. The substitution pattern is not present in any naturally occurring or semisynthetic tetracycline and imparts certain microbiologic properties to tigecycline. In general, tigecycline is considered bacteriostatic; however, TYGACIL has demonstrated bactericidal activity against isolates of S. pneumoniae and L. pneumophila. In vitro studies have not demonstrated antagonism between tigecycline and other commonly used antibacterials.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17012300
Curator's Comment: On average, the systemic exposure of tigecycline in bone, SF and CSF ranged from 11% to 41% of serum concentrations.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TYGACIL Approved Useis a tetracycline-class antibacterial drug indicated in patients 18 years of age and older for: Complicated skin and skin structure infections; Complicated intra-abdominal infections; Community-acquired bacterial pneumonia; Limitations of Use: TYGACIL is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia Launch Date2006 |
|||
Curative | TYGACIL Approved Useis a tetracycline-class antibacterial drug indicated in patients 18 years of age and older for: Complicated skin and skin structure infections; Complicated intra-abdominal infections; Community-acquired bacterial pneumonia; Limitations of Use: TYGACIL is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia Launch Date2006 |
|||
Curative | TYGACIL Approved Useis a tetracycline-class antibacterial drug indicated in patients 18 years of age and older for: Complicated skin and skin structure infections; Complicated intra-abdominal infections; Community-acquired bacterial pneumonia; Limitations of Use: TYGACIL is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia Launch Date2006 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.63 μg/mL |
50 mg 2 times / day multiple, intravenous dose: 50 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
TIGECYCLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.7 μg × h/mL |
50 mg 2 times / day multiple, intravenous dose: 50 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
TIGECYCLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.64 mg*h/L Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01560143 |
100 mg single, intravenous dose: 100 mg route of administration: intravenous experiment type: single co-administered: |
TIGECYCLINE serum | Homo sapiens |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
42.4 h |
50 mg 2 times / day multiple, intravenous dose: 50 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
TIGECYCLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11% |
50 mg 2 times / day multiple, intravenous dose: 50 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
TIGECYCLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 2 times / day multiple, intravenous Highest studied dose Dose: 100 mg, 2 times / day Route: intravenous Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
Disc. AE: Gastrointestinal disorder (NOS)... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (NOS) (50%) Sources: Page: p.223 |
300 mg single, intravenous Highest studied dose Dose: 300 mg Route: intravenous Route: single Dose: 300 mg Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
DLT: Gastrointestinal disorder NOS... Dose limiting toxicities: Gastrointestinal disorder NOS Sources: Page: p.223 |
100 mg single, intravenous MTD Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
Other AEs: Nausea, Vomiting... |
200 mg single, intravenous MTD Dose: 200 mg Route: intravenous Route: single Dose: 200 mg Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
Other AEs: Nausea, Vomiting... |
50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.10 |
unhealthy n = 3788 Health Status: unhealthy Condition: Complicated skin and skin structure infections Population Size: 3788 Sources: Page: p.10 |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (1%) Sources: Page: p.10Vomiting (1%) |
50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia Sources: Page: p.1 |
Disc. AE: Anaphylaxis, Anaphylactoid reaction... AEs leading to discontinuation/dose reduction: Anaphylaxis Sources: Page: p.1Anaphylactoid reaction Hepatic dysfunction NOS Liver failure Pancreatitis (grade 5) Fetal damage Tooth discoloration Diarrhea, Clostridium difficile |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Gastrointestinal disorder (NOS) | 50% Disc. AE |
100 mg 2 times / day multiple, intravenous Highest studied dose Dose: 100 mg, 2 times / day Route: intravenous Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
Gastrointestinal disorder NOS | DLT | 300 mg single, intravenous Highest studied dose Dose: 300 mg Route: intravenous Route: single Dose: 300 mg Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
Nausea | 50% | 100 mg single, intravenous MTD Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
Vomiting | 50% | 100 mg single, intravenous MTD Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
Nausea | 200 mg single, intravenous MTD Dose: 200 mg Route: intravenous Route: single Dose: 200 mg Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
|
Vomiting | 200 mg single, intravenous MTD Dose: 200 mg Route: intravenous Route: single Dose: 200 mg Sources: Page: p.223 |
healthy n = 6 Health Status: healthy Population Size: 6 Sources: Page: p.223 |
|
Nausea | 1% Disc. AE |
50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.10 |
unhealthy n = 3788 Health Status: unhealthy Condition: Complicated skin and skin structure infections Population Size: 3788 Sources: Page: p.10 |
Vomiting | 1% Disc. AE |
50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.10 |
unhealthy n = 3788 Health Status: unhealthy Condition: Complicated skin and skin structure infections Population Size: 3788 Sources: Page: p.10 |
Anaphylactoid reaction | Disc. AE | 50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia Sources: Page: p.1 |
Anaphylaxis | Disc. AE | 50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia Sources: Page: p.1 |
Diarrhea, Clostridium difficile | Disc. AE | 50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia Sources: Page: p.1 |
Fetal damage | Disc. AE | 50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia Sources: Page: p.1 |
Hepatic dysfunction NOS | Disc. AE | 50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia Sources: Page: p.1 |
Liver failure | Disc. AE | 50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia Sources: Page: p.1 |
Tooth discoloration | Disc. AE | 50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia Sources: Page: p.1 |
Pancreatitis | grade 5 Disc. AE |
50 mg 2 times / day multiple, intravenous Recommended Dose: 50 mg, 2 times / day Route: intravenous Route: multiple Dose: 50 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 36.0 |
no [IC50 >100 uM] | |||
Page: 36.0 |
no [IC50 >100 uM] | |||
Page: 36.0 |
no [IC50 >100 uM] | |||
Page: 36.0 |
no [IC50 >100 uM] | |||
Page: 36.0 |
no [IC50 >100 uM] | |||
Page: 36.0 |
no [IC50 >100 uM] | |||
Page: 36.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 36.0 |
inconclusive |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 5, 22 |
PubMed
Title | Date | PubMed |
---|---|---|
Meticillin-resistant Staphylococcus aureus hepatic abscess treated with tigecycline. | 2008 Aug |
|
Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines. | 2009 |
|
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). | 2010 Nov |
|
Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. | 2012 Jan 26 |
|
Tigecycline prevents LPS-induced release of pro-inflammatory and apoptotic mediators in neuronal cells. | 2013 Mar |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Sample Use Guides
Initial dose of 100 mg, followed by 50 mg every 12 hours administered intravenously over approximately 30 to 60 minutes.
Severe hepatic impairment (Child Pugh C): Initial dose of 100 mg followed by 25 mg every 12 hours.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18596149
Among the tested gram-positive isolates, tigecycline was most active as reflected by MIC50/MIC90 values against S. pyogenes (0.03/0.03 μg/ml) and S. pneumoniae (0.015/0.03 μg/ml), followed by S. aureus (0.12/0.25 μg/ml) and E. faecalis (0.12/0.5 μg/ml)
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:55:53 GMT 2023
by
admin
on
Sat Dec 16 15:55:53 GMT 2023
|
Record UNII |
70JE2N95KR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01AA12
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
||
|
NDF-RT |
N0000007948
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
||
|
NDF-RT |
N0000175938
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
||
|
WHO-VATC |
QJ01AA12
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
||
|
FDA ORPHAN DRUG |
406313
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
||
|
NDF-RT |
N0000007948
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
TYGACIL (AUTHORIZED SOFT TISSUE INFECTIONS)
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
||
|
LIVERTOX |
NBK547888
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
||
|
NCI_THESAURUS |
C258
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
220620-09-7
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
C119092
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
DTXSID2048581
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
Tigecycline
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
8115
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
1667643
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
CHEMBL376140
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
m10858
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
149836
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
70JE2N95KR
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
142708
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
C72865
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
70JE2N95KR
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
DB00560
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
SUB16467MIG
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
384455
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | RxNorm | ||
|
LL-84
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
TIGECYCLINE
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
2661
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
8172
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY | |||
|
100000089539
Created by
admin on Sat Dec 16 15:55:55 GMT 2023 , Edited by admin on Sat Dec 16 15:55:55 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DEGRADENT -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
BINDER->LIGAND |
The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 μg/mL).
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Trace amount; demonstrated some antibacterial activity in vitro, their activities were generally less than that of tigecycline and were effective against a narrower range of infectious
organisms (data on file at Wyeth Research)
MINOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MINOR
FECAL; PLASMA
|
||
|
METABOLITE -> PARENT |
Although both M5 and M6 demonstrated some antibac-
terial activity in vitro, their activities were generally less than that of
tigecycline and were effective against a narrower range of infectious
organisms (data on file at Wyeth Research).
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
Major peak in feces
MAJOR
FECAL; PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
AT STEADY-STATE |
|
||